10.71
-0.66 (-5.80%)
| Previous Close | 11.37 |
| Open | 11.23 |
| Volume | 2,242,266 |
| Avg. Volume (3M) | 1,672,947 |
| Market Cap | 1,257,621,376 |
| Price / Earnings (Forward) | 29.24 |
| Price / Sales | 4.03 |
| Price / Book | 2.37 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -20.39% |
| Operating Margin (TTM) | -31.40% |
| Diluted EPS (TTM) | -0.500 |
| Quarterly Revenue Growth (YOY) | 34.20% |
| Quarterly Earnings Growth (YOY) | 3,119.20% |
| Total Debt/Equity (MRQ) | 54.64% |
| Current Ratio (MRQ) | 11.93 |
| Operating Cash Flow (TTM) | 63.55 M |
| Levered Free Cash Flow (TTM) | 33.54 M |
| Return on Assets (TTM) | -0.07% |
| Return on Equity (TTM) | -10.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Dynavax Technologies Corporatio | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 0.58% |
| % Held by Institutions | 108.60% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Nov 2025 | Announcement | Dynavax to Participate at the 8th Annual Evercore Healthcare Conference |
| 05 Nov 2025 | Announcement | Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program |
| 05 Nov 2025 | Announcement | Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program |
| 22 Oct 2025 | Announcement | Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025 |
| 21 Oct 2025 | Announcement | Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |